When will the discussion on Dupixent's benefit be concluded?

Set the standard for applying for benefits for children and adolescents in one year

Key to future schedules such as cost-effectiveness and drug price negotiations

It does not seem easy for Dupixent, an atopic dermatitis treatment, to expand insurance benefits for children and adolescents.

 

According to related industries, Standard of Sanofi-Aventis Korea's Dupixent 200mg was recently set.

 

It is the first time in about a year since the application for expansion of benefits in March 2021.

 

Dupixent's expansion of atopic dermatitis benefits for children and adolescents took seven months to start consulting experts last year.

 

As it is an expensive new drug and it was not easy to register for the first time, it is judged that discussions on expansion are also difficult.

 

Although detailed indications are different, there is a clear difference in speed compared to JAK inhibitors such as Lilly Korea's Olumiant and Abbvie Korea's Rinvoq, which belatedly submitted applications for expanding atopic benefits.

 

JAK inhibitors are also relatively inexpensive.

 

Both drugs have been paid since this month.

 

Since it is a RSA drug and a separate dose of Dupixent 200mg has been added, it is necessary to go through the cost-effectiveness review process of the HIRA in the future as well as negotiations with the NHIS.

 

It remains to be seen whether Dupixent will be able to reach an agreement with the government and expand child benefits.

 

A company official said, "In the case of patients with severe childhood atopic dermatitis, treatment options with effects and safety information that can be used after local treatments are practically limited.

 

Sanofi will do its best to administer Dupixent to pediatric and adolescent patients as soon as possible." The current standard for Dupixent's health insurance coverage is when all patients with chronic severe atopic dermatitis aged 18 or older with a history of more than 3 years fall under the EASI (Extension Severity Evaluation Index) 23 or higher ▲even after 4 weeks of primary local treatment, the symptoms were not controlled, ▲ if a full-body immunosuppressant is administered for more than 3 months but has no response (more than 50% reduction in EASI) or cannot be used due to side effects, or ▲ before the start of Dupixent administration.

 

This includes the Dupixent 300 mg dose.